Tackling Hard Questions in Value

Author: Jennifer Bright, MPA, Executive Director, IVI For decades, we've known that untreated or poorly treated Major Depressive Disorder (MDD) is an enormous burden on individual patients, our health care system, and our society. Despite having this knowledge, there is much work to do in order to support and optimize cost-effective care for patients suffering [...]

2020-12-29T17:01:00-06:00September 9th, 2020|Blog|

Exploring Patient Heterogeneity and Diversity in Treatment Responses

Author: Jennifer Bright, MPA Everyone hopes for a COVID vaccine so our lives can return to normal. Yet, we know that even if clinical trials prove a vaccine's effectiveness, our society will still have to endure a long process of distribution. I'm personally willing to wait for a vaccine for healthcare workers, the elderly, and [...]

2020-12-29T17:01:22-06:00August 20th, 2020|Blog|

How do we identify and measure value for patients with rare diseases?

Authors: Annie Kennedy and Joff Masukawa. Rare diseases impact 1 in 10 Americans, and over 400 million people worldwide. The current development and FDA approval process can cost hundreds of millions of dollars – and take an average of 15 years – to develop one therapy. For the 30% of children diagnosed with a rare [...]

2020-12-29T17:01:46-06:00July 22nd, 2020|Blog|

Measuring Value: COVID-19 Forces a Reassessment

Authors: Patricia Deverka, Jennifer Bright, Louis Garrison, Samuel Nussbaum We have seen the COVID-19 pandemic decimate people’s lives, health care systems, and the global and US economy, with investments by the US government exceeding $4 trillion dollars and with unemployment approaching 20%. In recent days, numerous articles have speculated on the pricing for Gilead’s new [...]

2020-12-29T17:02:53-06:00May 20th, 2020|Blog|
Go to Top